Dr. Ravandi on Vadastuximab Talirine Plus Hypomethylating Agents in AML

Farhad Ravandi-Kashani, MD
Published: Sunday, Jun 25, 2017



Farhad Ravandi-Kashani, MD, professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses vadastuximab talirine plus hypomethylating agents (HMA) in acute myeloid leukemia (AML).

The CD33-directed antibody-drug conjugate vadastuximab talirine showed good tolerability in a phase I single-agent trial, says Ravandi, with the only toxicity being myelosuppression.

This led to a trial combining low doses of vadastuximab talirine with HMA, given on the last day of therapy with either azacitidine or decitabine.
 


Farhad Ravandi-Kashani, MD, professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses vadastuximab talirine plus hypomethylating agents (HMA) in acute myeloid leukemia (AML).

The CD33-directed antibody-drug conjugate vadastuximab talirine showed good tolerability in a phase I single-agent trial, says Ravandi, with the only toxicity being myelosuppression.

This led to a trial combining low doses of vadastuximab talirine with HMA, given on the last day of therapy with either azacitidine or decitabine.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x